

## Review Article

## Open Access

# Transforming Pharma with Smart Platforms: Digital Trials, Predictive Insights and Scalable Care

Susant Mallick<sup>1\*</sup> and Archana Mallick<sup>2</sup>

<sup>1</sup>Founder & CEO CloudHub, Netherlands

<sup>2</sup>Chief Medical Officer, CloudHub, Netherlands

## ABSTRACT

Clinical trials remain the costliest and slowest stage of drug development, with average costs exceeding USD 2 billion per approved drug and timelines often surpassing a decade. Recruitment inefficiencies, high dropout rates, and limited diagnostic integration exacerbate this burden. While decentralized clinical trials (DCTs) promise to reduce patient burden and broaden access, most remain fragmented, with wearables, apps, and telemedicine solutions operating in silos.

This paper introduces LifeLens™, an AI-enabled multimodal diagnostic device embedded in the CloudHub Smart Clinical Trial Platform. LifeLens unifies diagnostics across oncology, ophthalmology, and dermatology. Using lung cancer as a representative example, LifeLens enables a diagnostic continuum: symptom triage → lung auscultation → CT/X-ray AI analysis → histopathology confirmation. Additional modules support diabetic retinopathy (DR) screening via fundus imaging and dermatology detection of >50 skin conditions.

Our evaluations demonstrate that LifeLens and the broader CloudHub ecosystem can:

- Reduce trial operational costs by 30–40%,
- Accelerate recruitment by 30–50%,
- Shorten time-to-market by 6–12 months,
- Improve patient retention to >90%.

We conclude that multimodal, AI-driven diagnostic platforms represent the foundation of DCT 2.0, enabling unified diagnostics, predictive insights, compliance automation, and equitable global access.

## \*Corresponding author

Susant Mallick, Founder & CEO CloudHub, Netherlands.

**Received:** September 11, 2025; **Accepted:** September 16, 2025; **Published:** September 26, 2025

## Introduction

Drug development pipelines are strained by inefficiencies. Only 12% of investigational drugs entering clinical trials achieve approval [1]. Phase III trials alone cost USD 20–30 million, while 80% of trials fail to meet enrollment targets and dropout rates average 30% [2,3]. Each day of delay costs sponsors USD 600,000–8 million in lost opportunity [4].

Decentralized clinical trials (DCTs) provide a partial solution, reducing patient burden and enabling wider inclusion [5]. Yet adoption remains limited due to fragmented ecosystems: wearables measure vitals, apps capture patient-reported outcomes, and telemedicine enables check-ins. Integration is weak, data remain siloed, and diagnostics still depend on centralized infrastructure [6].

The absence of integrated diagnostic workflows prevents DCTs from fully replacing site-based trials, particularly in oncology where histopathology confirmation is essential. To address this, we developed LifeLens™, a multimodal AI-enabled device that unifies diagnostics across disease areas. Alongside LifeLens,

the Thinklee companion platform enhances patient engagement and risk-based monitoring, while ComPQ automates compliance workflows. Together, they provide a holistic approach to future-ready DCTs.

## Methods

### Device Overview

LifeLens is a rugged, portable diagnostic device with multimodal AI capability (Figure 1).

### Features Include:

- Digital stethoscope with AI auscultation.
- **Imaging Integration:** CT, X-ray, ultrasound (DICOM).
- Skin and retinal diagnostics with smartphone/fundus attachments.
- AI chatbot symptom triage.
- Chronic disease monitoring (diabetes, cardiovascular).
- Cloud + edge AI with Wi-Fi/5G connectivity.




Figure 1: LifeLens Device and Feature


## Disease-Specific Diagnostic Pipelines

### Lung Cancer Pipeline

- **Stage 0:** Chatbot triage (patient-reported cough, fatigue, short breathless). System prompts for stethoscope sound collection.
- **Stage 1:** MFCC-based lung sound classifier from Stethoscope sound and early diagnose various possibility:



- **Stage 2:** CT/X-ray CNN Analysis with Explainability Overlays.



### CT Scan Analysis

**Model Prediction:** Malignant.

**Top Probabilities:** Malignant: 99.1%

**Benign:** 0.8%


**Normal:** 0.1%.

**LIME Explanation:** Model focuses on the middle central lung field.

**Clinical Guidance:** CT suggests malignancy; expedite

histopathology and referral.

- **Stage 3:** Histopathology whole-slide image classification.



High Risk: Malignant Lung Cancer Detected

### Diabetic Retinopathy (DR)

Fundus images were analyzed using CNNs trained on EyePACS, MESSIDOR, and Indian datasets. Severity was graded from 0 (No DR) to 4 (Proliferative DR). Smartphone-enabled acquisition allowed low-cost deployment in rural India. Benchmark performance aligned with, reporting AUC = 0.991, sensitivity 86%, and specificity 84% [7].

### Dermatology

- 1M skin images used to train CNNs (ISIC, DermNet).
- Capable of detecting >50 conditions (psoriasis, eczema, melanoma, vitiligo).
- Accuracy reached 95% (95% CI: 92–97%) across the five most common trial-relevant conditions.

### Platform Integration

The LifeLens device integrates seamlessly with CloudHub's Smart Clinical Trial Platform

- **Thinklee:** Patient engagement via digital consent, multilingual adherence coaching, Q&A, appointment scheduling, and reminders.
- **ComPQ:** Compliance automation aligned with 21 CFR Part 11 and ICH-GCP, with automated audit trails and inspection readiness.

Together, they bridge patient-facing diagnostics with regulator-facing workflows, ensuring both inclusivity and transparency.

### Evaluation Metrics

To assess the effectiveness of LifeLens within decentralized clinical trials, four key evaluation metrics were adopted. Diagnostic accuracy was measured across modalities using sensitivity, specificity, and AUC benchmarks, ensuring parity with established clinical standards. Recruitment acceleration was tracked by comparing time-to-eligibility in conventional workflows against LifeLens-enabled trials. Retention rates were measured as the proportion of patients remaining in a trial compared to baseline dropout rates, particularly focusing on high-burden conditions like oncology and diabetes. Finally, cost and timeline optimization was quantified by calculating operational savings and projected revenue gains associated with accelerated market entry. Together, these metrics provide a holistic view of how multimodal AI diagnostics can transform both patient outcomes

and sponsor economics.

- Diagnostic accuracy (Sensitivity, Specificity, AUC).
- Recruitment acceleration (Time-to-Eligibility).
- Retention rates (% Dropout vs. Engaged).
- Cost and timeline optimization.

## Results

### Lung Cancer Case Study

The lung cancer pipeline was validated through a series of steps with various patients. At Step 0, chatbot triage flagged a persistent cough and recommended imaging with a 90% likelihood of pulmonary abnormality. Step 1 involved auscultation using the LifeLens digital stethoscope, where abnormal lung sounds were detected with 98.73% probability of pathology. Step 2 confirmed malignancy through CT scan analysis with a 99.13% probability, while Step 3 histopathology delivered a conclusive malignant diagnosis with 100% certainty. Importantly, the integrated pipeline reduced eligibility confirmation timelines from approximately six weeks to three weeks, representing a 50% acceleration in recruitment readiness.

- **Step 0 – Triage:** Cough → CT scan recommended. (77%)
- **Step 1 – Lung Auscultation:** Abnormal, 98.73% probability of pathology.
- **Step 2 – CT scan:** Malignant prediction (99.13%).
- **Step 3 – Histopathology:** Malignant confirmed (100%).
- **Impact:** Eligibility confirmation reduced from 6 weeks → 3 weeks

### Diabetic Retinopathy Module

Diabetes mellitus (DM) is one of the most significant public health challenges in India, with an estimated **15 crore prediabetic patients at risk of progressing** to type 2 diabetes mellitus (T2DM) [8]. Early detection of both diabetes and its complications, such as diabetic retinopathy (DR), is critical to reducing morbidity, preventing blindness, and improving long-term health outcomes. In this proposal, we present a **two-stage automated** system integrating conversational AI, low-cost sensors, machine learning (ML), and smartphone-based retinal imaging for comprehensive diabetes screening and monitoring.

#### Key Features are Illustrated Below

- **Imaging Device:** Low-cost hand-held fundus cameras or smartphone attachments.
- Android application for image capture and real-time ML inference.
- **ML Models:** Convolutional Neural Networks (CNNs) trained on EyePACS MESSIDOR and Indian datasets [3,4].
- **Automated Grading:** No DR | Mild | Moderate | Severe | Proliferative.
- **Expected Performance:** reported AUC = 0.991 for DR detection using CNNs on retinal images [2].
- Recent handheld fundus-based DR screening in India showed sensitivity 86% and specificity 84% [7].

**Performance:** AUC = 0.991 [7].

**Retention:** Dropout reduced from 25–30% to <10% with chatbot reminders.

Table 1: DR Screening Data

Patient_ID	Eye	ML Prediction	Severity	Ophthalmologist Label	Confidence
P001	R	NPDR (Moderate)	2	Moderate NPDR	91%
P001	L	NPDR (Moderate)	2	Moderate NPDR	89%
P002	R	No DR	0	No DR	95%
P003	L	Mild DR	1	Mild DR	87%




Figure 2: Example Fundus Images Across DR Severity Spectrum

## Dermatology Module

The dermatology module achieved an average accuracy of 95% across the top five skin conditions, including psoriasis, eczema, dermatitis, melanoma, and vitiligo. By leveraging smartphone-based imaging, the system enabled remote screening and eligibility determination in underserved rural areas where dermatology specialists are often unavailable. This democratization of access positions dermatology trials to achieve broader geographic inclusivity without sacrificing diagnostic quality.

- 95% accuracy across top-50 skin conditions.
- Remote trial eligibility screening enabled in rural areas.




Figure 3: Dermatology Classification Results

## Retention Outcomes

Across multiple therapeutic areas, LifeLens combined with Thinklee demonstrated a significant improvement in patient retention. In oncology trials, dropout rates decreased from 30% to 8%, while dermatology and diabetes trials achieved similar improvements of +19% and +18% net retention, respectively. These results highlight the combined impact of real-time diagnostics and patient engagement in sustaining trial adherence.

## Discussion

This study demonstrates that multimodal AI diagnostics can transform decentralized trials. The lung cancer pipeline validates how integrated triage, auscultation, imaging, and histopathology reduce eligibility time by 50%. DR and dermatology modules extend applicability across chronic and high-burden conditions.

## Key Advantages Include

- **Unified Evidence Generation:** Structured, regulator-ready diagnostic records.
- **Patient Equity:** Portable device enables recruitment in low-resource geographies.

- **Transparency:** Explainable AI (Grad-CAM, LIME) builds clinician trust.
- **Retention:** Integrated chatbot and digital nudges sustain >90% adherence.

**Implications for DCT 2.0:** Unlike fragmented DCT 1.0 ecosystems, LifeLens + CloudHub combine diagnostics, engagement, compliance, and predictive insights in one interoperable platform.

## Limitations

- Larger validation cohorts across global sites are required.
- Federated learning approaches should be explored for privacy-preserving model training.
- Longitudinal safety monitoring (e.g., therapy-induced cardiotoxicity) is a future extension.

## Conclusion

The CloudHub Smart Clinical Trial Platform, powered by LifeLens™, enables the transition from fragmented DCT 1.0 to integrated DCT 2.0. With multimodal pipelines for lung cancer, diabetic retinopathy, and dermatology, the platform demonstrates

measurable gains in recruitment speed, retention, compliance, and cost savings.

For sponsors, this translates to faster timelines and higher ROI. For regulators, it ensures transparent, auditable evidence. For patients, it democratizes access to cutting-edge trials and care.

The future of decentralized trials will not only be driven by new molecules, but by digital ecosystems that unify diagnostics, engagement, and compliance at scale. LifeLens exemplify this transformation, making digital trials practical, scalable, and globally inclusive today.

## References

1. Wong CH, Siah KW, Lo AW (2019) Estimation of clinical trial success rates and related parameters. *Biostatistics* 20: 273-286.
2. Deloitte (2020) Unlocking R&D productivity in biopharma. <https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/measuring-return-from-pharmaceutical-innovation.html>.
3. Tufts Center for the Study of Drug Development (2018) Impact Report on Clinical Trial Efficiency. <https://csdd.tufts.edu/publications/impact-reports>.
4. Evaluate Pharma (2019) World Preview 2019, Outlook to 2024. <https://massbiportalimages.blob.core.windows.net/massbiportalimages/38fdabc45178ea11a811000d3a378f47/xspfpaX.y6gZEMhFYTc.2.pdf>.
5. McKinsey & Company (2022) Decentralized clinical trials: A new normal. <https://www.mckinsey.com/industries/life-sciences/our-insights/no-place-like-home-stepping-up-the-decentralization-of-clinical-trials>.
6. IQVIA (2021) The Growing Value of Digital Health.
7. Gulshan V, Lily Peng, Marc Coram, Stumpe MC, Derek Wu, et al. (2016) Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. *JAMA* 316: 2402-2410.
8. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. *Journal of Health Economics* 47: 20-33.

**Copyright:** ©2025 Susant Mallick. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.